Perrigo acquires US rights to generic Xyzal
This article was originally published in Scrip
Perrigo has bought the US rights to market a generic version of UCB's Xyzal from Synthon Pharmaceuticals for an undisclosed amount. Perrigo now has exclusive US rights to levocetirizine tablets from Synthon, despite ongoing litigation between Synthon and UCB. The firms are engaged in a paragraph IV/Hatch-Waxman litigation over an ANDA filing by Synthon. In April, Synthon filed a US ANDA for generic Xyzal and expects 180 days of marketing exclusivity as it believes it is the first filer of the generic (Scrip Online, April 16th, 2008).